久保道德:桂枝茯苓丸治療子宮內膜異位症20例卵巢囊腫15例。日本產科與婦人科1979;7:128。
久保道德:桂枝茯苓丸之臨床應用。國外醫學、中醫中藥分冊1983;2:44。
王次南：木耳,蔗報月刊1990;65(9)13-5。
王心芬：五種黑色食品與其複方組合對血脂及LDL氧化之影響。國立臺灣大學食品科技研究所。2003碩士論文。王伯徹：食用及藥用菇系列報導(14),木耳,食品工業,1991;23(12):38-42,。王洪新：六味地黃丸加減治療消渴53例. 湖北中醫雜誌1987;(3):14-5。
王恩第等：中國中醫研究院中藥研究所六味地黃湯(丸)預防食管癌的實驗臨床資料匯編1988:49-50。
王道友：肥胖閉經治驗. 四川中醫,1997;15(8):40-41。
王玲、哈考賢、張遠等:功血寧對下丘腦－垂體－卵巢軸功能的影響. 山東中醫雜誌, 2001;20(2):106-7。
王玉革：六味地黃丸與更年康治療更年期綜合徵。浙江中西醫結合雜誌，2000; 10:461-2。
江伯源、林育諄：黑木耳道地美味又養生的黑英雄。 農藥世界雜誌, 2001;21(2):107-111。
水野卓、川合正允：菇類的化學生化學。國立編譯館。1997:297-303。
卯曉嵐：中國的食用與藥用大型真菌,微生物學通報1989;16:290-29。
池繩業等：運用六味地黃湯治療某些難治案之症的案例。上海中醫藥雜誌1984;(11):11-13。
余明哲、楊光正：六味地黃丸。中國中醫藥出版社。2006:10-23。
杜自疆：食用菇栽培技術,豐年社,1980;183-186。
杜金池、吳寬澤：台灣的木耳事業,台灣第七屆食用真菌研討會報告,1989;137-142
杜金池、鄭燮：台灣之木耳類,中國園藝, 1975;21：227-233。
李時珍：本草綱目,52卷,江西本校點本1~3冊,人民衛生出版社(1975~1978)。
李國達：針灸治療肥胖正近十年狀況。針灸臨床雜誌2000;(6):51-53。
李維欽：食用油脂、抗氧化劑與健康食品萃取物在C57BL/6小鼠血漿脂質及肝帳臟抗氧化酵素脂影響。國立陽明大學生物化學研究所。2000。碩士論文。李萍等：六味地黃丸和地黃的免疫藥理研究 中國免疫學雜誌,1987；(5):296。
李翠萍：補腎調法治療多發性卵巢綜合徵133例. 新中醫2006;38(1):51~52。
於英洲,江輝：六味地黃丸治療腎陰虧虛型糖尿病48例。實用中西醫結合雜誌，1995; 8:601。
吳普等(述),孫星衛、孫馮翼(輯)：神農本草經,3卷,嘉慶4年(1799)刊本復刻,商務印書館(1955)。
吳儀洛(編)：本草從新,18卷,瓶花書房,道光9年(1829)。
吳龍源，鄭浩元，陳旺全，施純全，彭文煌：滋陰補腎方對Streptozotocin誘發大鼠高血糖之降血糖功效。台灣中醫學雜誌2004；3(3)：37-46。
張介賓著：景岳全書。上海科學出版社，上海1984:168-169。
林茹玉：多囊性卵巢症候群影響因子之探討。臺北醫學大學公共衛生學系。碩士論文，台北，台灣，2004:11~13。
林晏瑜: 細胞色素3A4外顯子在中國的遺傳多型性研究，國立成功大學藥理學研 究所碩士論文，台南，台灣，1999:11~23。河上徵治：肥胖病漢方治療。現代東洋醫學1994；15﹙4﹚：22-25。
喜多島修也：防風通聖散，防己黃耆湯。肥胖證文12寸節反影響，日本東洋醫學會誌1993；43﹙5﹚：63-4。
周怡萱：六味地黃丸於高血脂症之臨床療效與安全性探討。國立臺灣大學/臨床藥學研究所碩士論文。台北，台灣，2001:11~13。周麗榮、俞瑾：補腎陰藥治療高胰島素高雄激素無排卵臨床觀察.中國中西醫結雜
誌1996;16(9):515~518。
周江海,餘清平：六味地黃丸合併黃連素治療老年糖尿病48例臨床分析。海峽藥學，1999; 11-12。
夏桂成:桂枝茯苓丸治療慢性附件炎慢性附件炎卵巢囊腫35例。江西中醫藥1960;8:49-50。
候立的:桂枝茯苓丸治療子宮肌瘤、卵巢囊腫類腫瘤性疾病30例。北京中醫1986;6:30-31。
侯信雄、吳龍溪：台灣蕈類之調查。 中國園藝, 1971; 17:1-14。
侯景文、俞瑾：肥胖、瘦素與多囊卵巢綜合徵。生殖醫學,1999;8 (3) : 135~138。
郎寧,王海松,元魯光：加減六味地黃丸治療2型糖尿病臨床觀察。成都中醫藥大學學報，2000; 23:46-47。
細野史郎:桂枝茯苓丸之臨床藥理解說。漢方臨床, 1977;1:14。
俞瑾、孫月麗、邵公權、邴聖民、李超荊:補腎化痰治療多囊卵巢綜合症中對下丘腦－垂體－卵巢功能的調節。中西醫結合雜誌, 1983;3:203。
陳志堯、袁九重:多囊性卵巢症候群(Polycystic ovarian syndrome,PCOS)
陳忠川：六味地黃丸之藥理及臨床應用。明通醫藥，1994；216:13-5。臨床醫學，2003;52(1):17-22。袁麗萍,陳麗娜,程蘭：益真Ⅱ號膠囊合大黃蟅丸治療多囊卵巢綜合徵20例療效觀察新中醫，2006;38(3):51-52。
曾柏凱：台灣地區多囊性卵巢症候群內分泌特性與濾泡液蛋白質表現之探討。碩士論文，台北，台灣，2004:11~13。原中琉璃子(日):和漢醫藥學會志，1985;2(3):562。
徐如唐譯：防風通聖散減肥作用的基礎研究﹙日﹚。國外醫學，中醫中藥分冊1995；17(3)：33。
馬伯良等：六味地黃湯（丸）的降血脂.中成藥研究, 1986;(12):41。
高美丁等：台灣地區體位與肥胖狀況“國民營養現況”,衛生署1998 ;(12)：143。.
孫月麗等：補腎化痰法治療多發性卵巢綜合徵133例。上海中醫藥雜誌,1981;6:14。
孫斐、俞瑾、笪翠娣等：雄激素致不孕大鼠肥胖-無排卵機制及滋腎陰藥減肥和促排卵作用,中華內分泌代謝雜誌 ,1999;15 (5) : 255~228。
孫月麗：補腎化痰治療多囊卵巢綜合症53例,上海中醫藥雜誌1981;6:14。許強：六味地黃丸可預防癌症,實用中西醫結合雜誌，1992;5(6):380。
唐慎徵(撰)：重修政和經史證類妙用本草，張存惠,晦明軒刊(蒙古定宗4年-1249)
中國古典醫學叢書刊本復刻，人民衛生出版社(1957)。
章巧萍：淺談補腎活血化瘀法治療多囊卵巢綜合徵。中國中醫藥信息雜誌,2004;11(11):1015。
翁維良：肥胖病研究進展,全國大四屆肥胖病研究學術會議紀要,中醫雜誌1995;36(5):303-05。
馮光榮、尤昭玲：補腎活血法治療多囊卵巢綜合徵.陝西中醫學院學報, 2003;27(2):63-65。
梅全喜：實用中西醫結合雜誌，1992;5(7):408-09。
陶弘景(撰)：本草經集注，中國古典醫學叢書刊本復刻, 群聯出版社(1955)。
寇宗爽(撰)：本草衍義，武昌醫學館柯氏校本，宣統2年(1910)。
陳香：溫補脾腎法治療女性肥胖併發閉經88例臨床觀察。
北京中醫,1998;(4):30。
陳啟楨：黑木耳減肥最健康，元氣齋出版社，初版，臺北市， 2002，P41~42。
陳嘉真：黑木耳液體發酵培養抑制腫瘤細胞生長及抗氧化活性之研究。南台科技大學化學工程系。2002。碩士論文。許勝發：六味地黃丸降血糖作用之研究。國立成功大學/藥理學研究所碩士論文。台南，台灣，2001:11~13。張寬智：袪淤化痰軟堅湯治療女性肥胖閉經52例.陜西中醫,1997;18(11):487。
張景岳：景岳全書。人民衛生出版社1985：86-88。
植田實正實(日)：:國外醫學中醫中藥分冊，1990;12(5):366。
黃宮繡：本草求真,卷七食物,宏業書局1980:192-193。
賈泰元：六味地黃丸的免疫調節作用,中成藥，1994;16(9):34。
趙瑞華：多囊卵巢綜合的徵研究進展。中國中醫藥信息雜誌,2004;11(6):551。
葉一萍：辨病與辨證結合治療多囊卵巢綜合徵。遼寧中醫學院學報,2004;6(4):310。
葉振聲：單一基因之內分泌疾病。臨床醫學, 2003; 52:23-28閔三弟：真菌的藥用價值。食用菌學報,1996;3(4):55-64。
楊雪媚：六味地黃丸（湯）研究進展。明通醫藥，1996；236: 6-10。楊勝、張永祥、呂曉東等：六味地黃湯對活性部位3A的免疫作用機理研究。中國中西醫結合雜誌, 2001 ; 21 (2) : 119~123。
楊新美：中國食用栽培學。農業出版社,1988;584-5。
楊學： 傅氏加味補中益氣湯治療肥胖不孕。實用醫技雜誌, 1996;3(3):204。
楊冬梓、石一復：小兒和青春期婦科學。北京人民衛生出版社, 2003;170-3。
鄒麗敏等：六味地黃湯對腎虛型肺癌患者的臨床作用及實驗研究。 北京中醫學院學報，1993;16(6):43。
廖麗美:桂枝茯苓丸治療小型子宮壁間肌瘤25例。山東醫刊,1966;3:14
趙桂蓉：木耳類之抗氧化性質及其多醣組成分析。國立中興大學食品科學系碩士論文，台中，台灣，1997;33~36。趙夢華等：六味地黃丸對冠心病患者血液流變學的影響。中成藥，1993;15(4):46。
趙樹儀等：六味地黃沖劑與六味地黃丸藥理作用的比較。中草藥，1991;22(4):165。
潘瑞亮：肥胖女性閉經的中醫治療。 中國農村醫學,1995;23(6):58。
劉喜英：中西醫結合治療肥胖閉經不孕56例體會。 山西醫學,1997;26(3):282
劉玉琦等：六味地黃湯對虛證動物的影響。 中成藥，1994;16(6):38。
劉波：中國藥用真菌。化工技術，1986;4(10):36-50。
劉保林等：六味地黃湯及其組方對小鼠血糖和肝糖元的影響。中國中藥雜誌，1991;16(7):437。
劉敘儀等：六味地黃丸或金匱腎氣丸輔助治療小細胞肺癌的療效觀察。中西醫結合雜誌，1990;10(12):720。
閻牙法、馮學升、姜梅芳:補腎活血中藥加克羅米芬治療多囊卵巢綜合徵所致不孕症32例臨床觀察。中醫雜誌, 2003; 44(1):39-40。
羅元愷:桂枝茯苓丸治療卵巢囊腫300例。中醫雜誌1994;6:355。
鄺安堃等：中醫陰陽的實驗研究IV中西醫結合雜誌，1985;(3):167。
蘇正元：五種黑色食品與其複方組合於體外試驗之抗氧化能力國立臺灣大學食品科技研究所。2002。碩士論文。蘇敬(著)，勻本為人(重輯)：重輯新修本草，學術圖書刊行會1978;2:43-44。
鐘磊等：六味地黃丸加減治療非胰島素依賴型糖尿病65例。 湖北中醫雜誌1992;14 (2):20。
Acbay O and Gundogdu S.1996. Can metformin reduce insulin resistance in polycystic ovary syndrome? Fertil Steril. 65:946–49.
Acien P, Quereda F and Matallin P.1999. Insulin, androgens, and obesity in women with and without polycystic ovary syndrome: a heterogenous group of disorders. Fertil Steril.71:32–40.
Adams J, Polson D and Franks S.1986. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br. Med. J. Clin. Res. Ed., 293, 355–59.
Adashi EY, Hsueh AJ and Yen SS. Insulin enhancement of luteinizing hormone and follicle-stimulating hormone release by cultured pituitary cells. Endocrinology 1981;1O8:I441-1449.
Armar NA, McGarrigle HH and Honour J.1990. Laparoscopic ovarian diathermy in the management of anovulatory infertility in women with polycystic ovaries: endocrine changes and clinical outcome. Fertil Steril. 53(1): 45-9.
Armar NA, Banu Z L TC and CookeID.2002. Long-term following up of pations with polycystic ovary syndrome after laparoscopic ovarian drilling: endocrine and utrasonographic outcomes. Hum. Reprod. 17(11):2851-57.
Armstrong VL, Wiggam MI, Ennis CN, Sheridan B, Traub AI, Atkinson AB and Bell PM.2001. Insulin action and insulin secretion in polycystic ovary syndrome treated with ethinyl oestradiol/cyproterone acetate. Q. J Med. 94:31–7.
Asunción M., Calvo RM, San Millán JL, Sancho J, Avila S and Escoar MHF.2000. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women in Spain. J. Clin. Endocrinol. Metab. 85:2434–43.
Azziz R.2006. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature, J Clin Endocrinol Metab. 91(3);781-5
Balen AH and Michelmore K.2002. What is polycystic ovary syndrome? Are national views important? Hum. Reprod 17 (9):2219-27.
Balen AH.1999. The pathogenesis of polycystic ovary syndrome: the enigma unravels. Lancet 354: 966–67.
Balen AH.2001. Polycystic ovary syndrome and cancer. Hum. Reprod. Update, 7: 522–25.
Balen A H, Conway GS, Kaltsas G, Techatrasak K, Manning PJ, West C and Jacobs HS. 1995. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum. Reprod. 10: 2107–11.
Banerji M, Faridi N, Atluri R, Chaiken R and Lebovitz H.1999.Body composition, visceral fat, leptin and insulin resistance in Asian Indian men. J Clin Endocrinol Metab 84:137-44.
Barbieri RL.1994. Hyperandrogenism, insulin resistance and acanthosis nigricans. 10 years of progress. J Reprod Med 39:327-36.
Barbieri RL.2000. Induction of ovulation in infertile women with hyperandrogenism and insulin resistance. Am J Obstet Gynecol.183:1412-18.
Barbieri RL.2003. Metformin for the treatment of polycystic ovary syndrome. Obstetrics & Gynecology 101(4): 85-93.
Barbieri RL and Gargiulo AR.2004. Metformin for the treatment of the polycystic ovary syndrome. Minerva Ginecologica. 56(1): 63-79.
Barbieri RL, Makris A, Randall RW, Daniels G, Kistner RW and Ryan KJ. 1986 Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab 62:904–10.
Bates Gw and Whitworth NS.1982. Effect of body weight reduction on plasma androgens in obese, infertile women. Fertil Steril. 38:406-9.
Bergh C, Carlsson B and Olsson JH.1993. Regulation of androgen production in cultured human thecal cells by insulin-like growth factor I and insulin. Fertil Steril.59:323-29.
Bernasconi D, Del Monte P, Meozzi M, Randazzo M, Marugo A, Badaracco B and Marugo M.1996. The impact of obesity on hormonal parameters in hirsute and nonhirsute women. Metabolism 45(1):72–5.
Bhatia V.2005. Insulin Resistance in Polycystic Ovarian Disease. Southern Medical Journal 98(9): 901-12.
Branch RA, Chern HD Adedoyin A Romkes-Sparks M Lesnick TG. Persad R Wilkinson G.R Fleming C M Dickinson AJ, and Sibley G..1995. The procarcinogen hypothesis for bladder cancer: activities of individual drug metabolizing enzymes as risk factors. Pharmacogenetics 5:97-102.
Bringer J, Lefebvre P and Boulet F.1993. Body composition and regional fat distribution in polycystic syndrome. Ann N Y Acad Sci. 687:115–23.
Broly F, Marez D, Sabbagh N, Legrand M, Millecamps S, Lo Guidice J M, Boome P and Meyer U A.1995. An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis. Pharmacogenetics 5: 373-84.
Burghen G A, Givens JR and Kitabchi AE.1980. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 50:113-6.
Botis D, Kassanos D, Pyrgiotis E and Zourlas PA.1995. Sonographic incidence of polycystic ovaries in a gynecological population. Ultrasound Obstet. Gynecol., 6: 182–85.
Baulieu EE and Robel P.1990. Neurosteroids: a new brain function? J Steroid Biochem Mol Biol 37:395–403.
Carmina E, Koyama T., Chang L, Stanczyk FZ and Lobo RA.1992. Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome? Am. J. Obs. Gynecol., 167: 1807–12.
Carmina E, Wong L, Chang L, Paulson RJ, Sauer MV, Stanczyk FZ and Lobo RA.1997. Endocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound. Hum. Reprod 12:905-9.
Cataldo NA and Giudice LC.1992. Follicular fluid insulin-like growth factor binding protein profiles in polycystic ovary syndrome. J Clin Endocrinol Metab 74:695-7.
Chandalia M, Abate N, Garg A, Stray-Gundersen, Jand Grundy SM.1999. Relationship between generalized and upper body obesity to insulin resistance in Asian Indian men .J Clin Endocrinol Metab 84：2329-35.
Chang C J , Wu CH, Chang CS, Yao WJ, Yang YC, Wu JS and Lu FH.2003. Low body mass index but high percent body fat in Taiwanese subjects: implications of obesity cutoffs. Int J Obes Relat Metab Disord. 27：253-59.
Chang RJ, Nakamur RM, Judd HL and Kaplan SA.1983. Insulin resistance in nonobese
patients with polycystic ovarian disease. J Clin Endocrinol Metab 57:356-9.
Cheng JT, Liu, IM, Chi TC, Su HC and Chang CG.. 2001.Metformin-like effects
of Quei-Fu-Die-Huang-Wan, a Chinese herbal mixture, on Streptozotocin-Induced
Diabetic Rat.Hormone & Metab. Res., 33: 727 - 732.
Cheng JT, Liu, IM, Chi TC, Su HC and Chang CG.. 2001.Stimulation of insulin release by Die-Huang-Wan, a herbal mixture used in Chinese traditional medicine.
Chereau A.1844. Mémoires pour Servir a l’étude des Maladies des Ovaries. Masson et Cie, Paris, France. Chereau A (1844) Mémoires pour Servir a l’étude des Maladies des Ovaries. Masson et Cie, Paris, France.
Cheung CK.1996. The hypocholesteromic effect of two edible mushroom. Auricularia auricula (tree-ear) and Tremella Fuciformis (white jelly-leaf) in hypercHolestero-
lemic rats. Nutrition Research, 16(10), 1721-25.
Cholerton S, Daly A K and Idle JR.1992. The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol. Sci.13: 434-39.
Clarke AM, Ledger W, Galletly C, Tomlinson L, Blaney F, Wang X and Norman RJ.1995. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum. Reprod. 10: 2705–12.
Clayton RN, Ogden V, Hodgkinson J, Worswick L, Rodin DA, Dyer S and Meade TW.1992. How common are polycystic ovaries in normal women and what is their significance for the fertility of the population? Clin. Endocrinol. (Oxf.) 37: 127–34.
Colhoun HM, McKeigue PM and Davey Smith G.2003. Problems of reporting genetic associations with complex outcomes. Lancet 361:865–72
Colilla S, Cox N J and Ehrmann DA.2001. Heritability of Insulin Secretion and Insulin Action in Women with Polycystic Ovary Syndrome and Their First Degree Relatives J. Clin. Endocrinol. Metab. 86 (5): 2027 - 31.
Conway G.S, Honour JW and Jacobs HS. 1989. Heterogeneity of the polycystic ovary syndrome: clinical, endocrine and ultrasound features in 556 patients. Clin. Endocrinol. (Oxf.). 30: 459–70.
Conway GS, Clark PM and Wong D.1993. Hyperinsulinaemia in the polycystic ovary syndrome confirmed with a specific immunoradiometric assay for insulin. Clin. Endocrinol. (Oxf.). 38: 219–22.
Coon M J, Ding X X Pernecky S J and Vaz A D.1992. Cytochrome P450: progress and predictions. FASEB J. 6: 669-73.
Corpechot C, Young J, Calvel M, Wehrey C, Veltz JN, Touyer G, Mouren M, Prasad VV, Banner C and Sjovall J.1993. Neurosteroids: 3a-hydroxy-5a-pregnan-20-one and its precursor in the brain, plasma, and steroidogenic glands of male, and female rats. Endocrinology;133:1003–9.
Costello, MF and Eden JA.2003. A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertil Steril. 79(1): 1-13.
Crave JC, Fimbel S and Lejeune H.1995. Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women. J Clin Endocrinol Metab. 80:2057–62.
Cresswell JL, Barker DJ, Osmond C, Egger P, Phillips DI and Fraser RB.1997. Fetal growth, length of gestation, and polycystic ovaries in adult life. Lancet, 350:1131–35.
Crosignani PG and Nicolosi AE.2001. Polycystic ovarian disease: heritability and heterogeneity. Hum Reprod Update 7:3-7.
Dahlgren E, Friberg LG, Johansson S, Lindstrom B, Oden A, Samsioe G and Janson PO. 1991. Endometrial carcinoma: ovarian dysfunction: a risk factor in young women. Eur J Obstet Gynecol Reprod Biol 41(2): 143–50.
Dahlgren E, Johansson S, Lindstedt G, Knutsson F, Oden A and Janson PO.1992. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones. Fertil Steril 57:505-13.
Daneshmand S, Weitsman SR, Navab A, Jakimiuk AJ and Magoffin DA.2002. Overe-
xpression of theca-cell messenger RNA in polycystic ovary syndrome does not correlate with polymorphisms in the cholesterol side-chain cleavage and 17_-hydroxylase/C(17–20) lyase promoters. Fertil Steril 77:274–80
DeFronzo RA and Goodman AM. 1995 Efficacy of metformin in patients with non-insu-
lin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med;333:541–9.
Degawa M, Stern S J, Martin M V Guengerich F P Fu P P Ilett K F Kaderlik R K and Kadlubar FF.1994. Metabolic activation and carcinogen-DNA adduct detectionin human larynx. Cancer Res. 54:4915-9.
De Leo V, La Marca A, Ditto A, Morgante G and Cianci A.1999. Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 72:282–5.
De Leo V, La Marca A and Petraglia F.2003. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev 24:633–67.
De Leo V, La Marca A, Orvieto R and Morgante G. 2000 Effect of metformin on insulin
-like growth factor (IGF) I and IGFbinding protein I in polycystic ovary syndrome. J Clin Endocrinol Metab 85:1598–600.
Deurenberg YM, Schmidt G Staveren WA and Deurenberg P.2000. The paradox of low body mass index and high body fat percentage P .The Chinese, Malays and Indians in Singapore. Int J Obes Relat Metab Disord. 24：1011-17.
Deurenberg YM and Staveren WA.1998. Body mass index and percent body fat：a meta analysis among different ethnic groups.Int J Obes Relat Metab Disord. 22:1164-71.
Dewailly D, Robert Y Helin I and Ardaens Y.1994. Ovarian stromal hypertrophy in hyperandrogenic women. Clin. Endocrinol 41: 557–62.
Diamanti Kandarakis E, Batzis MI, Bergiele AT, Tsianateli TC and Kouli CR.2000. Microsatellite polymorphism (tttta) at _528 base pairs of gene CYP11a influences hyperandrogenemia in patients with polycystic ovary syndrome. Fertil Steril 73:735–41
Diamanti K E, Spina G, Kouli CR, Bergiele AT, Filanora FA, Tsianteli TC and Spina G G.1999. A survey of. The polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 84:4006-11.
Diamanti K E, Kouli C, Tsianateli T and Bergiele A.1998. Therapeutic effects of metfor-
min on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol. 138:269-74.
Diamanti K E, Mitrakou A Hennes MJ Platanissiotis D Kaklas N Spina J Georgiadou E Hoffmann RG Kissebah AH and Raptis S.1995. Insulin sensitivity and antiandroge-
nic therapy in women with polycystic ovary syndrome. Metabolism 44: 525–31.
Douchi T, Ijuin H Nakamura S Oki T Yamamoto S and Nagata Y.1995. Bodyfat distribution in women with polycystic ovary syndrome. Obstet Gynecol, 86: 516–19.
Dunaif A.1997. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev, 18: 774-800.
Dunaif A.1999. Insulin action in polycystic ovary syndrome. Endocrinol Metab Clin North Am 28: 341-59.
Dunaif A and Finegood DT.1996. β-Cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab 81: 942–47.
Dunaif A and Graf M.1989. Insulin administration alters gonadal steroid metabolism independent of changes in gonadotropin secretion in insulinresistant women with the polycystic ovary syndrome. J Clin Invest 83:23-29.
Dunaif A, Graf M and Mandeli J. 1987. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsu-
linemia. J Clin Endocrinol Metab. 65:499-507
Dunaif A, Scott D and Finegood D. 1996. The insulin-sensitizing agent troglitazone im-
proves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab. 81:3299-306.
Dunaif A, Segal KR, Futterweit W and Dobrjansky A.1989. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38: 1165–74.
Dunaif A, Segal KR, Shelly DR, Green G, Dobrjansky A and Licholai T.1992. Evidence for distinctive and intrinsic defects in insulin action in the polycystic ovary syndrome. Diabetes 41: 1257–66.
Ebihara K, Schneeman BO.1989. Interaction of bile acid, phospholipids, cholesterol and triglyceride with dietary fiber in the small intestine of rats. J. Nutr. 119:1100-06.
Eenst E.2000. Prevalence of use of complementary/alternative medicine a systematic review Bull World Health Organ 78:252-57.
Ehrmann DA, Barnes RB and Rosenfield RL.1999. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22(1): 141-6.
Ehmann DA, Cavahan MK, Imperial J, Sturis J, Rosenfield RL, Polonsky KS.1997. Eff-
ects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 82:524-30.
Ehrmann DA, Sturis J Byrne MM Karrison T and Rosenfield RL.1995. Insulin secretory defects in polycystic ovary syndrome. J Clin Invest 96:520–27.
Elting MW, Korsen TJ, Bezemer PD and Schoemaker J.2001. Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population. Hum Reprod 16:556-60.
El-Roeiy A, Chen X, Roberts VJ, Shimasakai S, Ling N, LeRoith D, Roberts CT, Jr and Yen SS.1994. Expression of the genes encoding the insulin-like growth factors (IGF-I andII), the IGF and insulin receptors, and IGF-binding proteins-1-6 and the localization of their gene products in normal and polycystic ovary syndrome ovaries. J Clin Endocrinol Metab 78:1488-96.
Escobar MHF, Roldan B, Barrio R, Alonso M, Sancho J, Calle H and Garcia R R.2000. High prevalence of the polycystic ovary syndrome and hirsutism in women with type 1 diabetes mellitus. J Clin Endocrinol Metab 85:4182-7.
Evans DJ, Hoffmann RG, Kalkhoff RK and Kissebah AH.1983. Relationship of androgenic activity to body fat topography, fat cell morphology, and metabolic aberrations in premenopausal women. J Clin Endocr Metab 57(2):304–310.
Faray-Ewans L, Reyna R, Knochenhauer ES, Bartolucci AA and Azziz R.2004. Glucose action and adrenocortical biosynthesis in women with polycystic ovary syndrome. Fertil Steril 81:120–5.
Farquhar CM, Birdsall M, Manning P and Mitchell JM.1994. Transabdominal versus transvaginal ultrasound in the diagnosis of polycystic ovaries in a population of randomly selected women. Ultrasound Obstet. Gynecol. 4: 54–59.
Farquhar CM, Birdsall M, Manning P, Mitchell JM and France JT.1994. The prevalence of polycystic ovaries on ultrasound scanning in a population of randomly selected women. Aust. NZ J. Obstet. Gynaecol, 34: 67–72.
Faure N, Prat X, Bastide A and Lemay A.1989. Assessment of ovaries by magnetic resonance imaging in patients presenting with polycystic ovarian syndrome. Hum. Reprod. 4: 468–72.
Felix C A, Walker A H, Lange B J, Williams T M, Winick N J, Cheung N K, Lovett B D, Nowell P C, Blair I A and Rebbeck T R.1998. Association of CYP3A4 genotype with treatment-related leukemia. Proc. Natl. Acad. Sci. 95: 13176-13181. .
Fleming R, Hopkinson ZE and Wallace AM.2002. Ovarian function and metabolic fact-
ors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab 2002; 87:569–74.
.FonsecaV, Valiqueet TR, Huang SM, Ghazzi MN and Whitcomb RW.1998. Troglitazone monotherapy in patients with type 2 diabetes mellitus: a randomized controlled trial. J. Clin. Endocrinol. Metab. 83:3169-76.
.Fonseca V, Rosenstock J, Patwardhan R and Salzman A.2000. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA. 283(13): 1695-702.
Fox R, Corrigan E, Thomas PA and Hull MG..1991. The diagnosis of polycystic ovaries in women with oligomenorrhoea: predictive power of endocrine tests. Clin. Endocrinol. (Oxf.) 34: 127-31.
Fox R and Ryan A.2002. Polycystic ovary syndrome: not ovarian, not simple, unkind. Human Fertility. 5:28-32.
Franks S.1989. Polycystic ovary syndrome: a changing perspective. Clin. Endocrinol. (Oxf.) 31: 87–120.
Franks S.1995. Polycystic ovarian syndrome. N. Engl. J. Med., 333: 853–61.
Franks S.2006. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria. J Clin Endocrinol Metab. 93(3):786-9
Franks S and White DM.1993. Prevalence of and etiologieal factors in polycystic ovarian syndrome. Ann N Y Acad Sci 687:l 12-14.
Franks S, Gharani N, Waterworth D, Batty S, White D, Williamson R and McCarthy M.1997. The genetic basis of polyscystic ovary syndrome. Hum. Reprod., 12: 2641–48.
Franks S, Gharani N and McCarthy M.2001. Candidate genes in polycystic ovary syndrome. Hum. Reprod. Update, 7: 405–10.
Fulghesu AM, Ciampelli M, Belosi C, Apa R, Pavone V and Lanzone A.200. A new ultrasound criterion for the diagnosis of polycystic ovary syndrome: the ovarian stroma/total area ratio. Fertil. Steril. 76: 326–31.
Gaasenbeek M, Powell B L Sovio U Haddad L Gharani N Bennett A Groves C J; Rush K, Goh M J Conway G S Ruokonen A Martikainen H Pouta A Taponen S Hartikainen AL Halford S Jarvelin MR Franks Sand McCarthy M I.2004. Large-Scale Analysis of the Relationship between CYP11A Promoter Variation, Polycystic Ovarian Syndrome, and Serum Testosterone. J Clin Endocrinol Metab. 89(5): 2408-13.
Gaasenbeek Michelle, Powell Brenda L, Sovio Ulla, Haddad Lema, Gharani Neda, Bennett Amanda, Groves Christopher J, Rush Karen, Goh Micaela J, Conway, Gerard S, Ruokonen Aimo, Martikainen Hannu, Pouta Anneli, Taponen Saara, Hartikainen, Anna-Liisa; Halford, Stephanie; Jarvelin, Marjo-Riitta; Franks, Steve; McCarthy and Mark I.2004. Large-Scale Analysis of the Relationship between CYP11A Promoter Variation, Polycystic Ovarian Syndrome, and Serum Testosterone. J Clin Endocrinol Metab. 89(5):2408-13.
Gadir AA, Khatim MS, Mowafi RS, Alnaser HM, Muharib NS and Shaw RW.1992. Implications of ultrasonically diagnosed polycystic ovaries. I. Correlations with basal hormonal profiles. Hum. Reprod., 7, 453–57.
Gambineri A, Pelusi C, Genghini S, Morselli LAM, Cacciari M, Pagotto U and Baracat EC.2004. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertil. Steril. 81(2): 355-60.
Ged C, Rouillon J M, Pichard L, Combalbert J, Bressot N, Bories P, Michel H, Beaune P and Maurel P.1989. The increase in urinary excretion of 6 beta-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br. J. Clin. Pharmacol. 28: 373-387.
Genazzani AD. Application of peak-detection programs to clinical data. In: Guardabasso V, Rodbard D and Forti G.1990. ditors. Computers in endocrinology: Recent advances. New York: Raven Press;. pp 71–82.
Genazzani AD, Battaglia C, Malavasi B, Strucchi C, Tortolani F and Gamba O.2004. Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertil. Steril.;81:114–9.
Genazzani AD, Battaglia C, Gamba O, Petraglia F, Malavasi B and Genazzani AR.2000. The use of a combined regimen of GnRH agonist plus a low-dose oral contracep-
tive improves the spontaneous pulsatile LH secretory characteristics in patients with polycystic ovary disease after discontinuation of treatment.J Assist Reprod Genet 17:269–275.
Genazzani AD, Luisi M, Malavasi B, Strucchi C, Luisi S, Casarosa E, Bernardi F, Genazzani AR, Petraglia F.2002. Pulsatile secretory characteristics of allopregnanolone, a neuroactive steroid, during the menstrual cycle and in amenorrheic subjects. Eur J Endocrinol 146:347–356.
Genazzani AD, Petraglia F, Battaglia C, Gamba O, Volpe A and Genazzani AR.1997. A long-term treatment with gonadotropinreleasing hormone agonist plus a low-dose oral contraceptive improves the recovery of the ovulatory function in patients with polycystic ovary syndrome. Fertil Steril 67:463–468.
Genazzani AD, Petraglia F, Fabbri G, Monzani A, Montanini V and Genazzani AR. 1990. Evidence of luteinizing hormone secretion in hypothalamic amenorrhea associated with weight loss. Fertil Steril 54:222–6.
Genazzani AD, Petraglia F, Benatti R, Montanini V, Algeri I,Volpe A, Genazzani AR. 1991. Luteinizing hormone (LH) secretory burst duration is independent from LH, prolactin or gonadal steroid plasma levels in amenorrheic women. J Clin endocrinol Metab 72:1220–1225.
Genazzani AD, Petraglia F, Pianazzi F, Volpogni C, Genazzani AR.1993. The concomitant release of androstenedione with cortisol and luteinizing hormone pulsatile releases istinguishes adrenal from ovarian hyperandrogenism.Gynecol Endocrinol 7:33–41.
Genazzani AD and ard D.1991. Evaluation of methods for detection of pulsatile hormone secretion: sensitivity vs.specificity. Acta Endocrinol (Copenh) 24:295–306.
Gharani N, WaterworthDM,Batty S, White D, Gilling-Smith C, Conway GS, McCarthy M, Franks S and WilliamsonR.1997. Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism. Hum Mol Genet 6:397–402
Genazzani AR, Petraglia F, Bernardi F, Casarosa E, Salvestroni C, To netti A, Nappi RE, Luisi S, Palumbo M and Purdy RH.1998. Circulating levels allopregnanolone in humans: gender, age, and endocrine influences. J Clin Endocrinol Metab. 83:2099–103.
Giudice LC.1999. Growth factor action on ovarian function in polycystic ovary syndrome. Endocrinol Metab Clin North Am.28: 325-39
Gilling SC, Willis DS, Beard RW and Franks S.1994. Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries. J Clin Endocrinol Metab. 79: 1158-65.
Gilling S C, Story H, Rogers V and Franks S.1997. Evidence for a primary abnormality of thecal cell steroidogensis in the polycystic ovary syndrome. Clin. Endocrinol. 47: 93–99.
Glueck CJ, Phillips H, Cameron D, Sieve S L and Wang P.2001. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril 75:46-52.
Gokcel A, GumurduluY, Karakose H, Melek E E, Tanaci N and Bascil TN.2002. Evaluation of the safety and efficacy of sibutramine,orlisat and metformin in the treatment of obesity .Diabetes Obes Metab;4:49-55
Gonzalez A, Abril E, Roca A, Aragon M J, Figueroa M J, Velarde P, Ruiz R, Fayez O, Galan J J, Herreros J A, Real L M and Ruiz A.2003. Specific CAPN10 Gene Haplotypes Influence the Clinical Profile of Polycystic Ovary Patients. J Clin Endocrinol Metab. 88(11):5529-36.
Guengerich F P.1988. Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450. Mol. Pharmacol. 33:500-08.
Guengerich F P.1990. Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. Chem. Res. Toxicol. 3, 363-71.
Guengerich F P.1995. Human cytochromes P450. In P. R. Ortiz de Montellano , Cytochromes P450 : Structure, Mechanism, and Biochemistry, Plenum Press, New York, pp. 473-535.
Goldzieher JW. 1981. Polycystic ovarian disease. Fertil. Steril. 35: 371–394.
Gurrici S, Hartriyanti Y, Hautvast JG and Deurenberg P.1998. Relationship between body mass index：difference between indonesians and Dutch Caucasians Eur J Clin Nutr 52:779-83
Harborne L, Fleming R, Lyall H, Norman J and Sattar N.2003. Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. Lancet. 361(9372):1894-901.
Haas DA, Carr BR and Attia GR.2003.Effects of metformin on body mass index, menstrual cyclicity, and ovulation induction in women with polycystic ovary syndrome. F & S. 79(3): 469-81.
Haddad L, Evans JC, Gharani N, Robertson C, Rush K, Wiltshire S, Frayling TM, Wilkin TJ, Demaine A, Millward A, Hattersley AT, Conway G, Cox NJ, Bell GI, Franks S and McCarthy MI.2002. Variation within the type 2 diabetes susceptibility gene calpain-10 (CAPN10) and polycystic ovary syndrome. J Clin Endocrinol Metab 87:2606–10
Hasegawa I, Murakawa H and Suzuki M.1999. Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome. Feiiil Steril 71:323-27.
Heaney D, Majid A and Junor B. 1997 Bicarbonate haemodialysis as a treatment of metformin overdose. Nephrol Dial Transplant 12:1046–7.
Hickey T, Chandy A and Norman RJ.2002. The Androgen Receptor CAG Repeat Polymorphism and Xchromosome Inactivation in Australian Caucasian Women with Infertility Related to Polycystic Ovary Syndrome. J Clin Endocrinol Metab 87:161-5.
Holte J, Bergh T, Berne Ch, Berglund L and Lithell H.1994. Enhanced early insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance. J Clin Endocrinol Metab 78,1052–58.
Holte J, Bergh T, Berne Ch, Wide L and Lithell H.1995. Restored insulin sensitivity but persistantly increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 80,2586–93.
Homburg R, Pariente C, Lunenfeld B and Jacobs HS.1992. The role of insulin-like growth factor-1 (IGF-1) and IGF binding protein-1 (IGFBP-1) in the pathogenesis of polycystic ovary syndrome. Hum Reprod 7:1379-83.
Horejsi R, Möller R, Pieber TR, Wallner S, Sudi K, Reibnegger G and Tafeit E.2002. Differences of subcutaneous adipose tissue topography (SAT-Top) in type-2 diabetic men and healthy controls. Exp Biol Med 227:794–98.
Hou J, Yu J and Wei M.2000. Study on treatment of hyperandrogenism and hyperinsulin in polycystic ovary syndrome with Chinese herbal formula “tiangui fang”.Zhongguo Zhong Xi Yi Jie He Za Zhi. 20(8): 589-92
Hung MH, Yang RC and Hu SH.1996. Preliminary results of triple therapy for obesity. 20(9)：830-36
Hunt C M, Westerkam W R and Stave G. M.1992. Effect of age and gender on the activity of human hepatic CYP3A. Biochem. Pharmacol. 44: 275-283.
Ibanez L, de Zegher F and Potau N.1998. Premature pubarche, ovarian hyperandrogenism, hyperinsulinism and the polycystic ovary syndrome: from a complex constellation to a simple sequence of prenatal onset. J Endocrinol Invest 21:558-66.
Ibanez L, Valls C, Ferrer A, Ong K, Dunger DB and Zengher F.2002. Additive effects of insulin-sensitizing and anti-androgen treatment in young, non obese women with hyperinsulinism, hyperandrogenism, dyslipidemia and anovulation. J Clin Endocrinol Metab 7:2870–4.
Ibanez L, Valls C, Ferrer A, Marcos MV, Rodriguez Hierro F and De Zengher F. 2001 Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism. J Clin Endocrinol Metab 86:3595–8.
Ioannidis JPA, Ntzani EE, Trikalinos TA and Contopoulos-Ioannidis JG.2001. Replication validity of genetic association. Nat Genet 29:306–9
Isojarvi IT, Laatikainen T, Pakarinen AJ, Juntunen KTS and Myllyla VV.1993. Polycystic ovaries and hyperandrogenism in women taking valporate for epilepsy. N. Engl. J. Med., 329, 1383–88.
Jakimiuk AJ, Weitsman SR, Navab A, Magoffin DA 2001 Luteinizing hormone receptor, steroidogenesis acute regulatory protein, and steroidogenic enzyme messenger ribonucleic acids are overexpressed in thecal and granulose cells from polycystic ovaries. J Clin Endocrinol Metab 86:1318–23
Jayagopal V, Kilpatrick ES, Holding S, Jennings PE, Atkin SL.2002. Thebiological variation of insulin resistance on polycystic ovarian syndrome. J Clin Endocrinol Metab. 87(4):1560–62.
Kahn CR, Flier JS, Bar RS, Archer JA, Gorden P, Martin MM and Roth J.1976. The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. N Engl J Med. 294:739–745.
Kalow W, GoeddeHW and Agarwal DP.1986. Ethnic Differences in Reactions to Drugs and Xenobiotics, AR Liss, New York.
Kaminsky L S and Fasco M J.1991. Small intestinal cytochromes P450. Crit. Rev. Toxicol. 21:407-22.
Katsuki A, Sumida Y and Murashima S.1996. Acute and chronic regulation of serum sex hormone-binding globulin levels by plasma insulin concentrations in male non-insulin dependent diabetes mellitus patients. J Clin Endocrinol Metab 81: 2515-19.
Keckstein G, Roscsmanith W, Spatzier V, Schneider V, BrochersK and Steiner R. 1990. The effect of laparoscopic treatment of polycystic ovarian disease by CO2-laser or Nd:YAG laser. Surg Endosc.4:103-7.
Kelly J D, Eaton DL, Guengerich F P and Coulombe R A.1997. Aflatoxin B1 activation in human lung. Toxicol Appl Pharmacol 144: 88-95.
Kelly C, Lyall H Petrie JR.2002. A specific elevation in tissue plasminogen activator antigen in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 87: 3287-90.
Kelly C, Lyall H, Petrie JR, Gould GW, Connell JM and Sattar N.2001. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 86: 2453-55.
Kiddy D S, Sharp P, White DM, Scanlon MF, Mason HD, Bray CS, Polson DW, Reed MJ and Franks S.1990. Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases. Clin. Endocrinol. (Oxf.) 32: 213–220.
Kirchengast S and Huber J.2001. Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum Reprod . 16(6):1255–60.
Knochenhauer ES, Key TJ, Kahsar M M, Waggoner W, Boots LR and Azziz R.1998. Prevalence of the polycystic ovary syndrome in unselected Black and White Women of the Southeastern United States: A prospective study. J. Clin. Endocrinol. Metab. 83:3078–82.
Kocak M, Caliskan E, Haberal B and Simsir C.2002. Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome, Fertil. Steril. 77(1): 101-6.
Ko GT, Chan JC, Cockram C S and Woo J.1999. Prediction of hypertension, diabetes, dyslipidaemia or albuminuria using simple anthropometric indexes in Hong Kong Chinese .Int J Obes Relat Metab Disord 23：1136-1142
Kolars J C, Awni W M, Merion R M and Watkins P B.1991. First-pass metabolism of cyclosporin by the gut. Lancet .338: 1488-1490.
Kolodziejczyk B, Duleba A, Spaczynski R and Pawelczyk L.2000. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril 73: 1149-54.
Kye M A, Maconochie N, Zaidi J, Pittrof R, Campbell S and Tan SL.1996. Transvaginal three-dimensional ultrasound: reproducibility of ovarian and endometrial volume measurements. Fertil Steril. 5: 718–22.
La Marca A, Egbe TO, Morgante G, Paglia T, Ciani A and De Leo V.2000. Metformin treatment reduces ovarian cytochrome P-450c17a response to human chorionic gonadotrophin in women with insulin resistance-related polycystic ovary syndrome. Hum Reprod 15:21–23.
Lasco A, Cucinotta D, Gigante A, Denuzzo G, Pedullo M, Trifiletti A and Frisina N.1995. No changes of peripheral insulin resistance in polycystic ovary syndrome after long-term reduction of endogenous androgens with leuprolide. Eur J Endocrinol 133:718–22.
Lefebvre P, Bringer J, Renard E, Boulet F, Clouet S and Jaffiol C.1997. Influences of weight, body fat patterning and nutrition on the management of PCOS. Hum Reprod. 12:72–81.
Legro RS.1995. The genetics of polycystic ovary syndrome.Am J Med 98:9-16.
Legro RS.1998. Spielman R, Urbanek M, Driscoll D, Strauss JF and Dunaif A. Phenotype and genotype in polycystic ovary syndrome. Recent Prog Horm Res 53:217-56.
Legro RS, Driscoll D, Strauss JF, Fox J and Dunaif A.1998. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci USA 95:14956-60.
Legro RS, Finegood D and Dunaif A.1998. Fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 83:2694–8.
Linde K, Joan WB, Melchart D and Willich S.2001. The metholological quality of trandomized controlled trials of homeopathy herbal medicines and acupuncture Int J Epidemiol 30:526-31
Lin TC, Weng SP, Lin WS and KuoTC.2002. The effectiveness of Metformin therapy in women with polycystic ovary syndrome. Taiwanese J. Obst.Gynecol. 41(2):43-52.
Lin TC, Wu MJ, Gong KB, Chu YC, Tu PL, Lee WT and Kuo TC .2003.Abnormal glucose tolerance or insulin resistance amongst the Taiwanese PCOS women – not correlated with IRS-1 Gly972Arg/Ala513Pro polymorphism Taiwanese J. Obst.Gynecol. 42(3):34-42.
Lin WY , Lee LT, Chen CY, Lo H, Hsia HH, Liu IL, Lin RS, Shau WY and Huang KC. 2002. Optimal cut-off values for obesity：using simple anthropometric indices to predict cardiovascular risk factors in Taiwan. Int J Obes Relat Metab Disord. 26：1232-38.
Lobo RA and Carmina E.2000. The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med 132: 989-93.
Lohmueller KE, Pearce CL, Pike M, Lander ES and Hirschhorn JN.2003. Metaanalysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 33:177–82
Lord JM, Flight IH and Norman RJ.2003. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ. 327(7421): 951-3.
Lowy B.1951. A morphological basis for classifying the species of Auricularia. Mycologia. 43: 351-58.
Lowy, B.1952. The genus Auricularia. Mycologia. 44: 656-92.
Lucky AW, Rosenfield RL, McGuire J, Rudy S and Helke J.1986. Adrenal androgen hyperresponsiveness to adrenocorticotropin in women with acne and/or hirsutism: adrenal enzyme defects and exaggerated adrenarche. J Clin Endocrinol Metab 62:840–8.
MacDougall MJ, Tan SL Balen A and Jacobs HS.1993. A controlled study comparing patients with and without polycystic ovaries undergoing in-vitro fertilization. Hum. Reprod. 8: 233–36.
Maciel GA, Soares JM, Alves DA, Motta EL, Haidar M, Lima GR and Baracat EC.2004. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertility & Sterility, 81(2): 355-60.
Mason HD, Margara R, Winston RM, Seppala M, Koistinen R and Franks S.1993. Insulin-like growth factor-I (IGFI) inhibits production of IGF-binding protein-1 while stimulating estradiol secretion in granulosa cells from normal and polycystic human ovaries. J Clin Endocrinol Metab 76:1275-9.
Mehta RV, Patel KS and Coffler MS.2005. Luteinizing hormone secretion is not influenced by insulin infusion in women with polycystic ovary syndrome despite improved insulin sensitivity during pioglitazone treatment. J Clin Endocrinol Metab. 90:2l36-41.CYP11
Michelmore KF, Balen AH, Dunger DB and Vessey MP.1999. Polycystic ovaries and associated clinical and biochemical features in young women. Clin. Endocrinol. (Oxf.) 51: 779–86.
Michelmore KF, Ong K, Mason S, Bennett S, Perry L, Vessey MP, Balen AH and Dunger DB.2001. Clinical features in women with polycystic ovaries: relationships to insulin sensitivity, insulin gene VNTR and birth weight. Clin. Endocrinol. 55:439– 46.
Mifsud A, Ramirez S and Yong EL.2000. Androgen Receptor Gene CAG Trinucleotide Repeats in Anovulatory Infertility and Polycystic Ovaries J. Clin. Endocrinol. Metab. 85(9): 3484–88.
Mellon SH and Deschepper CF.1993. Neurosteroid biosynthesis: genes for adrenal steroidogenic enzymes are expressed in the brain. Brain Res 629:283–92.
Moghetti P, Castello R and Negri C.1996. Insulin infusion amplifies 17-a-hydroxycor-
ticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women: apparent relative impairment of 17,20-lyase activity. J Clin Endocrinol Metab. 81:881- 6.
Moghetti P, Castello R and Negri C.2000. Metformin effects on clinical features, end-
ocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab.85:139–46.
Möller R, Tafeit E, Smolle KH, Pieber TR, Ipsiroglu O, Duesse M, Huemer C, Sudi K and Reibnegger G.2000a. Estimating percentage total body fat and determining subcutaneous adipose tissue distribution with a new non-invasive optical device Lipometer. Am J Hum Biol 12:221– 30.
Möller R, Tafeit E, Pieber TR, Sudi K and Reibnegger G.2000b. Measurement of subcutaneous adipose tissue topography (SAT-Top) by means of a new optical device, Lipometer, and the evaluation of standard factor coefficients in healthy subjects. Am J Hum Biol 12:231–9
Möller R, Tafeit E, Sudi K and Reibnegger G.2000c. Quantifying the “appleness”or “pearness” of the human body by subcutaneous adipose tissue distribution. Ann Hum Biol 27(1): 47–55.
Morais SM, Wilkinson G.R, Blaisdell J, Nakamura K, Meyer U A and Goldstein JA.1994.The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol. Chem. 269:15419-22.
Morales AJ, Laughlin GA, Butzow T, Maheshwari H, Baumann G and Yen SSC.1996. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab 81,2854–64.
Moran C, Reyna R, Boots LS and Azziz R. 2004 Adrenocortical hyperresponsiveness to corticotropin in polycystic ovary syndrome patients with adrenal androgens excess. Fertil Steril 81:126–31.
Morin-Papunen LC, Koivunen RM, Ruokonen A and Martikainem HK.1998. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril ; 69: 691-96.
Morin-Papunen LC, Vahkonen I and Koivunen RM Ruokonen A and Tapanainen JS.2000. Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovary syndrome. Hum Reprod 15:1266–74.
Morin-Papunen L, Vauhkonen I and Koivunen R.2003. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab. 88:148–156.
Morin-Papunen LC, Vauhkonen I and Koivunen RM.2000. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab. 85:3161–68.
Murray G. I., McFadyen M C, Mitchell R T, Cheung Y L, Kerr A C and Melvin WT. 1999. Cytochrome P450 CYP3A in human renal cell cancer. Br. J. Cancer 79, 1836-42.
Nagamani M and Stuart CA.1990. Specific binding sites for insulin-like growth factor I in the ovarian stroma of women with polycystic ovarian disease and stromal hyperthecosis. Am J Obstet Gynecol 163:1992-7.
Nam C, Kim S, Sim Y and Chang I.2003. Anti-acne effects of Oriental herb extracts: a novel screening method to select anti-acne agents. Skin Pharmacol Appl Skin Physiol. 16(2): 84-90.
Nardo LG and Rai R.2001 Metformin therapy in the management of polycystic ovary syndrome:endocrine, metabolic and reproductive effects. Gynecol Endocrinol.15:
373–80.
Nelson D R, Kamataki T, Waxman D J, Guengerich F P, Estabrook R, W Feyereisen R, Gonzalez F J, Coon M J, Gunsalus I C, Gotoh O, Okuda K and Nebert D W.1993. The P450 super-family : update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol. 12: 1-51.
Nelson D R, Koymans L, Kamataki T, Stegeman J J, Feyereisen R, Waxman D J, Waterman M R, Gotoh O, Coon M J, Estabrook R W, Gunsalus I C and Nebert DW .1996. P450 super-family : update on new sequences, gene mapping accession numbers and nomenclature. Pharmacogenetics 6:1-42.
Nelson VL, Legro RS, Strauss III JF, McAllister JM.1999. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol 13:946–57
Nestler JE, Clore JN, Strauss 3rd JF, Blackard WG. I987. The effects of hyperinsulinemia on serum testosterone, progesterone, dehydroepiandrosterone sulfate, and cortisol levels in normal women and in a woman with hyperandrogenism, insulin resistance, and acanthosis nigricans. J Clin Endocrinol Metab.64:18O-184.
Nestler JE and Jakubowicz DJ.1997. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin Endocrinol Metab; 82:4075–79.
Nestler JE and Jakubowicz DJ.1996. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med. 335:617–623.
Nestler JE, Jakubowicz DJ, Evans WS and Pasquali R.1998. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med. 338:1876-80.
Nestler JE, Stovall D, Akhter N, Iuorno MJ and Jakubowicz DJ.2002. Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Fertile Steril 77:209-15.
Ng EH, Wat NM and Ho PC.2001. Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial. Hum Reprod .16:1625–31.
Ng MC, Young R P, Critchley J A, Leung N, W Lau J W and Li A K.1996. Urinary 6 beta-hydroxycortisol excretion in Hong Kong Chinese patients with hepatocellular carcinoma and other chronic liver diseases. Cancer 77: 1427-33.
O'Driscoll JB, Mamtora H, Higginson J, Pollock A, Kane J and Anderson DC.1994. A prospective study of the prevalence of clear-cut endocrine disorders and polycystic ovaries in 350 patients presenting with hirsutism or androgenic alopecia. Clin. Endocrinol. (Oxf.). 41: 231–6.
Ovalle F and Azziz R.2002. Insulin resistance, the polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril. 77:1095–105.
Ovesen P, Moller J, Ingerslev HJ, Jorgensen JO, Mengel A, Schmitz O, Alberti KG and Moller N.1993. Normal basal and insulin-stimulated fuel metabolism in lean women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 77 :1636–40.
Pache TD, Jong FH, Hop WC and Fauser BCJM.1993. Association between ovarian changes assessed by transvaginal sonogrophy and clinical and endocrine signs of the polycystic ovary syndrome. Fertil. Steril. 59: 544–49.
Pan WH, Flegal KM, Chang HY, Yeh CJ, Yeh WT and Lee WC.2004.Body mass index and obesity-related metabolic disorders in Taiwanese and US whites and blacks implications for definitions of overweight and obesity for Asians Am J Clin Nutr 79：31-39
Park KH, Kim JY, Ahn CW, Song YD, Lim SK and Lee HC.2001. Polycystic ovarian syndrome (PCOS) and insulin resistance. Int J Gynaecol Obstet.74:261–7.
Pasquali R and Casimirri F.1993. The impact of obesity on hyperandrogenism and polycystic ovary syndrome in premenopausal women. Clin Endocrinol 39 : 1–16.
Pasquali R, Casimirri F, Venturoli S, Paradisi R, Mattioli L, Capelli M, Melchionda N and Labo G.1983. Insulin resistance in patients with polycystic ovaries: its relationship to body weight and androgen levels. Acta Endocrinol 104:110–116.
Pasquali R.2004.Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clinical Endocrinology. 60(2): 241-49.
Pasquali R, Gambineri A and Biscotti D.2000. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab. 85: 2767- 74.
Pasquali R, Vicennati V and Gambineri A.1998. Influence of weight and distribution
of adipose tissue in functional hyperandrogenism. Contraception Fertilité Sexualité 26(5): 372–5.
Patel K, Coffler MS and Dahan MH, 2003 Increased luteinizing hormone secretion in women with polyeystic ovary syndrome is unaltered by prolonged insulin infusion. J Clin Endocrinol Metab. 88:5456-61.
Paul SM and Purdy RH. 1992 Neuroactive steroids. FASEB J 6:2311–2322.
Peiris AN, Mueller RA, Struve MF, Smith GA and Kissebah AH.1987. Relationship of androgenic activity to splanchnic insulin metabolism and peripheral glucose utilization in premenopausal women. J Clin Endocrinol Metab 64:162-9.
Peserico A, Angeloni G., Bertoli P, Marini A, Piva G., Panciera A and Suma V.1989. Prevalence of polycystic ovaries in women with acne. Arch. Dermatol. Res. 281: 502–3.
Polson DW, Adams J, Wadsworth J and Franks S.1988. Polycystic ovaries–a common finding in normal women. Lancet 1: 870–72.
Poretsky L, Cataldo NA, Rosenwaks Z and Giudice LC.1999. The insulin-related ovarian regulatory system in health and disease. Endocr Rev 20:535-82.
Poretsky L, Chandrasekher YA, Bai C, Liu HC, Rosenwaks Z and Giudice L. Insulin 1996 receptor mediates inhibitory effect of insulin, but not of insulin-like growth factor (IGF)-I, on IGF binding protein 1 (IGFBP-1) production in human granulosa cells. J Clin Endocrinol Metab;81:493-6.
Rajkowha M, Glass MR, Rutherford AJ, Michelmore K and Balen AH.2000. Polycystic Ovary Syndrome: a risk factor for cardiovascular disease? Br. J. Obs. Gynaecol. 107:11–18.
Rebbeck T R, Jaffe J M, Walker A H, Wein A J and Malkowicz S B.1998. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. Natl. Cancer Inst. 90:1225-29.
Rebuffé-Scrive M, Cullberg G, Lundberg PA, Lindstedt G and Björntorp P.1989. Anthropometric variables and metabolism in polycystic ovarian disease. Horm Metabol Res 21:391–7.
Robel P and Baulieu EE. 1994 Neurosteroids: biosynthesis and function. Trends Endocrinol Metab 5:1–8.
Rodin DA, Bano G, Bland JM, Taylor K and Nussey SS.1998. Polycystic ovaries and associated metabolic abnormalities in Indian subcontinent Asian women. Clin. Endocrinol. 1: 91–99.
Rose PG..1996. Endometrial carcinoma. N Engl J Med. 335:640-9.
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised.
2003.consensuson diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 81: 19-25.
Rouzi AA and Ardawi MM.2001. Insulin resistance in women with polycystic Ovarian syndrome contributed to cardiovascular disease risk factors independent of obesity. Fertil Steril 76(3):296–99.
San Millan JL, Sancho J, Calvo RM, Escobar-Morreale HF 2001 Role of the pentanucleotide (tttta)(n) polymorphism in the promoter of the CYP11a gene in the pathogenesis of hirsutism. Fertil Steril 75:797–802
Saxton DW, Farquhar CM, Rae T, Beard RW, Anderson MC and Wadsworth J.1990. Accuracy of ultrasound measurements of female pelvic organs. Br. J. Obstet. Gynaecol. 97:695–99.
Schuetz EG, Schuetz JD, Grogan W.M, Naray FT, A Fejs TG,. Raucy J, Guzelian P, Gionela K and Watlington CO.1992. Expression of cytochrome P450 3A in amphibian, rat, and human kidney. Arch. Biochem. Biophys.294: 206-14.
Sekiya N, Kainuma M, Hikiami H, Nakagawa T, Kouta K, Shibahara N, Shimada Y and Terasawa K.2002. Oren-gedoku-to and Keishi-bukuryo-gan-ryo Inhibit the Progression of Atherosclerosis in Diet-Induced Hypercholesterolemic Rabbits. Biol. Pharm. Bull. 28(2): 294-98.
Shimada T, Martin M V, Pruess S D, Marnett L J and Guengerich F P.1989. Roles of individual human cytochrome P-450 enzymes in the bioactivation of benzo pyrene, 7,8-dihydroxy-7,8-dihydrobenzopyrene, and other dihydrodiol derivatives of polycyclic aromatic hydrocarbons. Cancer Res. 49:6304-12.
Shimada T, Yamazaki H, Mimura M, Inui Y and Guengerich F P.1994. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals : studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270:414-23.
Shoupe D, Kumar DD and Lobo RA.1983. Insulin resistance in polycystic ovary syndrome. Am J Obstet Gynecol 147:588–92.
Sills E S, Mark PerloeM, TuckerMJ, Kaplan C R, Genton M G and Schattman GL.2001. Diagnostic and treatment characteristics of polycystic ovary syndrome: descriptive measurements of patient perception and awareness from 657 confidential self-reports BMC Women's Health 1:3-5
Sills ES, Perloe M and Palermo GD.2000. Correction of hyperinsulinemia in oligoovulatory women with clomiphene-resistant polycystic ovary syndrome: a review of therapeutic rationale and reproductive outcomes. Eur J Obstet Gynecol Reprod Biol. 91:135-41.
Soldani R, Cagnacci A, Yen SS. 1994. Insulin, insulin-like growth factor I (IGF-I) and IGF-II enhance basal and gonadotrophin-releasing hormone-stimulated luteinizing hormone release from rat anterior pituitary cells in vitro. Eur J Endoerinol 1994; 131:641-645.
Soldani R, Cagnacci A and Paoletti AM.1995. Modulation of anterior pituitary luteinizing hormone response to gonadotropin-releasing hormone by insulin-like growth factor I in vitro. Feriil Sleril. 64:634-637.
Solomons CG.1999. The epidemiology of polycystic ovary syndrome-prevalence and associated disease risks. Endocrinol. Metab. Clinics of North America.28: 247–63.
Solomon CG, Hu FB and Dunaif A.2002. Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab 87: 2013-17.
Solomon CG, Hu FB and Dunaif A.2001. Long or highly irregular menstrual cycles as a marker for risk of type II diabetes mellitus. JAMA 286 : 2421-26.
Stein IF and Leventhal ML.1935. Amenorrhea associated with bilateral polycystic ovaries. Am J Obs Gynecol 29:181–86.
Stein IF.1964. Duration of infertility following ovarian wedge resection. West J Surg. 72: 237-12.
Sun MT, Xiao JT and Yang Z.1982. Effect of certain Chinese foods on serum cholesterol and liver lipid levels in rats. Acta Nutrimenta Sinica 4(1): 45.
Tafeit E, Möller R, Pieber TR, Sudi K and Reibnegger G.2000. Differences of subcutaneous adipose tissue topography in type 2 diabetic (NIDDM) Women and healthy controls. Am J Phys Anthropol 113:381–8.
Tafeit E, Möller R, Rackl Giuliani A Urdl. Freytag U Crailsheim K Sudi K and Horejsi R.2003. Subcutaneous Adipose Tissue Pattern in Lean and Obese Women with Polycystic Ovary Syndrome Exp Biol Med 228:710–16.
Tafeit E, Möller R, Sudi K, Horejsi R, Berg A and Reibnegger G.2001. Orthogonal factor coefficient development of subcutaneous adipose tissue topography (SAT-Top) in girls and boys. Am J Phys Anthropol 115:57–61.
Tafeit E, Möller R, Sudi K and Reibnegger G.1999. The determination of three subcutaneous adipose tissue compartments in non-insulin-dependent diabetes mellitus women with artificial neural networks and factor analysis. Art Intell Med 17:181–93.
Takahashi K, Eda YA, Musa A, Okada S, Yoshino K and Kitao M.1994. Transvaginal ultrasound imaging, histopathology and endocrinopathy in patients with polycystic ovarian syndrome. Hum. Reprod. 9: 1231–36.
Tang J, Zhan S and Emst E.1999. Review of randomized controlled trials of traditional Chinese medicine BMJ 319:160-61
Tateishi, T, Krivoruk Y, Wood A J J, Guengerich F P and Wood M.1994. Identification of human liver P450 3A4 as the enzyme responsible for sulfentanil N-dealkylation, in : Abstracts, 12th Int. Congr. Pharmacol. (July24-29,Montreal).
Tayob Y, Robinson G., Adams J, Nye M, Whitelaw N, Shaw RW, Jacobs HS and Guillebaud J.1990. Ultrasound Appearance of the ovaries during the pill-free interval. Br. J. Family Planning, 16: 94–96.
The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group 2004 Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19:41–47.
Tokuda S, Tagiri A, Kano E, Sugawara Y, Suzuki S, Sato H and Kaneda T.1974 Reducing mechnism of plasma cholesterol by shiitake.Mushroom Sci.9:445-462.
Toprak S, Yonem A, Cakir B, Guler S, Azal O, Ozata M and Corakci A.2001. Insulin resistance in nonobese patients with polycystic ovary syndrome. Horm Res 55: 65–70.
Ukai S, Kiho T, Hara C, Kuruma I and Tanaka Y. 1983 Polysaccharides in fungi. XIV. Anti-inflammatory effect of the polysaccharides from the fruit bodies of several fungi. Journal of Pharmacobio-Dynamics. 6(12):983-90.
Urbanek M, Legro RS, Driscoll DA, Azziz R, Ehrmann DA, Norman RJ, Strauss JF 3rd Spielman RS and Dunaif A.1999. Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proc Natl Acad Sci USA 96:8573-8.
Urbanek M, Wu X, Vickery KR, Kao LC, Christenson L K, Schneyer A, Legro R S, Driscoll D A, Strauss J F, Dunaif A and Spielman R S.2000. Allelic Variants of the Follistatin Gene in Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab. 85(12): 4455 - 61.
Vahouny GV, Khalafi R, Satchithanandam S, Watkins DW, Story JA, Cassidy Me and Kritchevsky D.1987 Dietary fiber supp;ememtation and fecal bile acids, neutral steroids and divalent cations in rats.J.Nutr.117：2009-2015.
Van Dessel HJ, Chandrasekher YA and Yap OW.1996. Serum and follicular fluid levels of IGF-I, IGF-II and binding protein-1 (IGFBP-1) and IGFBP-3 during the normal menstrual cycle. J Clin Endocrinol Metab. 81:1224-31
Vanky E, Kjotrod SB, Maesel A, Bjerve KS and Carlsen SM.2004. Dexamethasone reduces androgen levels in metformin-treated patients with polycystic ovary syndrome. Fertil Steril. 81: 459–62.
Van Santbrink EJP, Hop WC and Fauser BC.1997. Classification of normogonadotropic infertility: polycystic ovaries diagnosed by ultrasound versus endocrine characteristics of polycystic ovary syndrome. Fertil. Steril. 67:452–58.
Velazquez E, Acosta A and Mendoza SG.1997. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet Gynecol. 90:392-405.
Velazquez EM, Mendoza S, Hamer T, Sosa F and Glueck CJ.1994. Metformin therapy in polycystic ovary syndrome